| Specificity |
This product is specific for Semaglutide. |
| Immunogen |
Semaglutide |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.1-1 μg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| Storage Instructions |
The lyophilized product remains stable for up to 1 year at -20 °C from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Human IgG1. κ |
| Clonality |
Monoclonal |
| Clone ID |
M1HC |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
The binding of Anti-Semaglutide Antibody (M1HC), Human Chimeric (GenScript, A02296) with Semaglutide, GLP-1, and Tirzepatide was tested using ELISA.
The coating antigen used was either Semaglutide, GLP-1, or Tirzepatide, each at a concentration of 4 μg/mL. The Anti-Semaglutide Antibody (M1HC), Human Chimeric (GenScript, A02296) was used at dilutions starting from 10 μg/mL. The results demonstrate that the antibody specifically recognizes Semaglutide and GLP-1 but does not recognize Tirzepatide.
| Target Background |
Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the GLP-1 hormone that is released in the gastrointestinal tract in response to eating. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar). |
| Synonyms |
Semaglutide, semaglutide, Ozempic, Rybelsus, Wegovy, NN9535, NN-9535, OG217SC, NNC 0113-0217, 910463-68-2, 53AXN4NNHX, CHEBI:167574, GTPL9724, A10BJ06, EX-A2424, AC-32580 |
| Reference |
US Food and Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss[J]. Accessed October, 2023, 29. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
